RNS & Investor News

OptiBiotix invited to present at Expoquimia in Barcelona

07 September 2017

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces it has been invited to present its research and commercial developments at the 18th edition of Expoquimia-World Chemical Summit ('Expoquimia') in Barcelona, Spain, on 5 October 2017.

Expoquimia is a multidisciplinary event held triennially in which the industry, professional associations, governments and academia come together to discuss future opportunities and challenges in industrial chemistry and biotechnology. In its previous edition, it had over 600 exhibitors and 38,000 visitors, making it one of the largest industrial chemistry events in Europe.

The Company will present the presentation titled: 'New approaches: microbiome modulation as therapeutic intervention', which will provide an overview of the wide array of existing strategies to modulate the microbiome to support human health, with a special focus on OptiBiotix's technology platforms for the development of novel prebiotics and probiotics.

Stephen O'Hara, CEO of OptiBiotix, commented: "This invitation shows that OptiBiotix is being increasingly regarded as a key player in microbiome science and industrial biotechnology. The interest in our OptiScreen® and OptiBiotic® platforms suggests that the industry believes we are developing commercially-attractive products that will need to be manufactured at an industrial scale in the near future. We are very excited to take part and feel very honoured and thankful to the organisers for considering us."


For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001


About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.